[Co-tetroxazin levels in the prostatic secretion of patients with subacute and chronic prostatitis].
Plasma and prostatic fluid concentrations of co-tetroxacine (TXP/SDZ) were investigated on 12 patients with subacute or chronic prostatitis. Co-tetroxacine was given perorally, 2 x 2 tabl. daily. - Tetroxoprime-(TXP-)concentrations in prostatic fluid were 4.2 micrograms/ml and 4.5 micrograms/ml 3 and 6 hours after peroral application (days 2 and 3) respectively. Compared to the concentrations of TXP in the systemic fluid there was an increase by the factor 3 to 4.3. - The corresponding concentrations of sulfadiazine (SDZ) in prostatic fluid were 11.6 micrograms/ml and 10.0 micrograms/ml - i.e. 62-70% of the plasma concentrations.
D000890:Anti-Infective Agents / Q000378:metabolism; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D001826:Body Fluids / Q000378:metabolism; D002908:Chronic Disease; D004338:Drug Combinations / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011467:Prostate / Q000378:metabolism*; D011472:Prostatitis / Q000188:drug therapy / Q000378:metabolism*; D011743:Pyrimidines / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D013411:Sulfadiazine / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D011743:Pyrimidines; D013411:Sulfadiazine; C023507:tetroxoprim; C026860:sulfadiazine, tetroxoprim drug combination
Co-tetroxazin-Konzentrationen im Prostatasekret von Patienten mit subakuter und chronischer Prostatitis.